In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Adverum Biotechnologies, Inc.. Trade Record

NASDAQ:ADVM Adverum Biotechnologies, Inc. stock gains 21.05% Exit Jan 9, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ADVM Dec 18, 2017, priceSeries
About Adverum Biotechnologies, Inc.

Avalanche Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
96.08
Entry Date
Dec 18, 2017
Entry Price
3.20
Sell Date
Jan 9, 2018
Sell Price
3.87
Net Gain
21.05%
Hold Time
14 Trading Days